Synthesis of water soluble bis-triazenoquinazolines: An unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase

Chemical Biology and Drug Design

Volumn 71, Issue 4, 2008, Pages 374-379

  Larroque, Anne Laure ^a   Peori, Brad ^a   Williams, Christopher ^b   Fang, You Qiang ^a   Qiu, Qiyu ^a   Rachid, Zakaria ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Bis triazenes; EGFR inhibitors; Molecular modeling

Indexed keywords

BISTRIAZENOQUINAZOLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; WATER;

ARTICLE; DOSE RESPONSE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG SYNTHESIS; IC 50; MOLECULAR MODEL; PRIORITY JOURNAL; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

EID: 40449130528     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00638.x     Document Type: Article

References (16)

1. 1 Modjtahedi H., Dean C. (1994) The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review). Int J Oncol ; 4: 277–296.
2. 2 Ilekis J.V., Connor J.P., Prins G.S., Ferrer K., Niederberger C., Scoccia B. (1997) Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol ; 66: 250–254.
3. 3 Scoccia B., Lee Y.M., Niederberger C., Ilekis J.V. (1998) Expression of the ErbB family of receptors in ovarian cancer. J Soc Gynecol Investig ; 5: 161–165.
4. 4 Brader K.R., Wolf J.K., Chakrabarty S., Price J.E. (1998) Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncol Rep ; 5: 1269–1274.
5. 5 Bast R.C. Jr, Pusztai L., Kerns B‐J., Macdonald J.A., Jordan P., Daly L., Boyer C.M. et al. (1998) Coexpression of the HER‐2 gene product, p185HER‐2, and epidermal growth factor receptor, p170EGF‐R, on epithelial ovarian cancers and normal tissues. Hybridoma ; 17: 313–321.
6. 6 Ellerbroek S.M., Hudson L.G., Stack M.S. (1998) Proteinase requirements of epidermal growth factor‐induced ovarian cancer cell invasion. Int J Cancer ; 78: 331–337.
7. 7 Li D., Ji H., Zaghlul S., McNamara K., Liang M‐C., Shimamura T., Kubo S. et al. (2007) Therapeutic anti‐EGFR antibody 806 generates responses in murine de novo EGFR mutant‐dependent lung carcinomas. J Clin Invest ; 117: 346–352.
8. 8 Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., Diorio C. et al. (1997) Induction of apoptosis and cell cycle arrest by CP‐358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res ; 57: 4838–4848.
9. 9 Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B. et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off‐rate, and receptor activity in tumor cells. Cancer Res ; 64: 6652–6659.
10. 10 Stamos J., Sliwkowski M.X., Eigenbrot C. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4‐anilinoquinazoline inhibitor. J Biol Chem ; 277: 46265–46272.
11. 11 Rachid Z., Brahimi F., Katsoulas A., Teoh N., Jean‐Claude B.J. (2003) The combi‐targeting concept: chemical dissection of the dual targeting properties of a series of “Combi‐Triazenes”. J Med Chem ; 46: 4313–4321.
12. 12 Tsou H.R., Mamuya N., Johnson B.D., Reich M.F., Gruber B.C., Ye F., Nilakantan R. et al. 6‐Substituted‐4‐(3‐bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER‐2) tyrosine kinases with enhanced antitumor activity. J Med Chem ; 44: 2719–2734.
13. 13 Manning H.W., Cameron L.M., LaFrance R.J., Vaughan K., Rajaraman R. (1985) Triazene metabolism. V. Chemical and biological properties of N,N‐bis[(1‐aryl‐3‐methyltriazene‐3‐yl)‐methyl]‐methylamines: potential prodrugs for the cytotoxic monomethyltriazenes. Anticancer Drug Des ; 1: 37–43.
14. 14 Rachid Z., Brahimi F., Qiu Q., Williams C., Hartley J.M., Hartley J.A. et al. (2007) Novel nitrogen mustard‐armed combi‐molecules for the selective targeting of epidermal growth factor receptor overexpressing solid tumors: discovery of an unusual structure‐activity relationship. J Med Chem ; 50: 2605–2608.
15. 15 Rewcastle G.W., Murray D.K., Elliott W.L., Fry D.W., Howard C.T., Nelson J.M., Roberts B.J. et al. (1998) Tyrosine kinase inhibitors. 14. Structure‐activity relationships for methyl‐amino‐substituted derivatives of 4‐[(3‐bromophenyl)amino]‐6‐(methylamino)‐pyrido[3,4‐d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J Med Chem ; 41: 742–751.
16. 16 Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J. et al. (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res ; 62: 5749–5754.